BABehnam Alipoor

Behnam Alipoor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Behnam Alipoor has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Circulating Levels of miR-155 and CTBP1-AS2 as a Promising Biomarker for Early Detection of Diabetic Nephropathy

    by Arezoo Rahimi, Shekoofeh Nikooei, Khatere Roozbehi, Davood Semirani-Nezhad, Rozina Abbasi Larki, Arash Arya, Danial Gholami, Behnam Alipoor

    Diabetic nephropathy (DN) is one of the most frequent complications of diabetes mellitus. Since the early diagnosis of DN is crucial to prevent the progression of the disease towards renal failure, many efforts have been made in recent years to introduce new diagnostic biomarkers. Recent studies suggest that non-coding RNAs could act as a novel diagnostic biomarker for the early detection and prediction of DN progress. Accordingly, in the current study we investigated the expression levels of miR-155 and CTBP1-AS2 in type 2 diabetes (T2D), DN patients and control subjects, and evaluated their diagnostic potential for DN. A total of 189 age and sex-matched subjects including 65 T2D patients with normo-albuminuria, 61 DN patients who had a history of albuminuria, and 63 control subjects were included in this case–control study. The expression levels of miR-155 and CTBP1-AS2 were determined using QRT-PCR. The results revealed that the expression level of miR-155 was significantly reduced in T2D patients. In addition, miR-155 level was significantly higher in DN patients with macroalbuminuria compared to DN patients with microalbuminuria and T2D patients with normo-albuminuria. The expression level of CTBP1-AS2 in T2D without proteinuria was higher than DN subjects with macroalbuminuria. The results also showed that there was a significant positive correlation between the miR-155 level with DBP, TG, TC, SCr and, BUN levels and a negative correlation with HDL-C and eGFR values. Deregulation levels of miR-155 and CTBP1-AS2 may represent useful novel diagnostic biomarkers for DN. Graphical Abstract


  • Open Access

    Current trends in single‐cell RNA sequencing applications in diabetes mellitus

    by Seyed Sajjad Zadian, Khodakaram Jahanbin, Shekoofeh Nikooei, Marzieh Rostaminejad, Arezoo Rahimi, Pedram Abdizadeh, Behnam Alipoor

    Diabetes mellitus (DM) is among the most prevalent metabolic diseases worldwide, associated with an increased risk of mortality. Although numerous studies have been conducted to uncover the cellular and molecular pathways associated with DM pathogenesis, reaching new diagnosis and treatment goals for DM requires further research. The progress in gene sequencing technologies, particularly in single‐cell RNA sequencing (scRNA‐seq), has yielded additional insights into the molecular pathways involved in the development and progression of DM. This review summarizes the latest advances and applications of RNA‐seq technologies in diabetes research, such as the characterization of single human islet and immune cells in DM, and the applications of scRNA‐seq in the treatment and early diagnosis of diabetes complications.


  • Open Access

    miR-27a/b Level is Associated with ABCA1 Expression and is a Potential PBMC-Based Biomarker for Coronary Artery Disease

    by Farshad Mirzavi, Safieh Ebrahimi, Arezoo Rajabian, Hossein Hosseini, Behnam Alipoor

    Background: Coronary artery disease (CAD) is the most common form of cardiac disease with high morbidity and mortality rates. Objectives: In this study, we evaluated the expression of miR-27a and miR-27b as biomarkers in peripheral blood mononuclear cells (PBMCs) of patients with CAD and investigated its correlation with cholesterol-efflux transporter, ATP-binding cassette transporter A1 (ABCA1). Method: This study was performed on 54 men with CAD and 51 healthy, sex- and age-matched control participants. The expression of miR-27a/b and ABCA1 [...] Abstract Background: Coronary artery disease (CAD) is the most common form of cardiac disease with high morbidity and mortality rates. Objectives: In this study, we evaluated the expression of miR-27a and miR-27b as biomarkers in peripheral blood mononuclear cells (PBMCs) of patients with CAD and investigated its correlation with cholesterol-efflux transporter, ATP-binding cassette transporter A1 (ABCA1). Method: This study was performed on 54 men with CAD and 51 healthy, sex- and age-matched control participants. The expression of miR-27a/b and ABCA1


  • Open Access

    Circulating Levels of HOTAIR- lncRNA Are Associated with Disease Progression and Clinical Parameters in Type 2 Diabetes Patients

    by Nafiseh Niknam, Shekoofeh Nikooei, Hassan Ghasemi, Seyed Sajjad Zadian, Kamran Goudarzi, Seyed Majid Ahmadi, Behnam Alipoor

    Background: Recent studies have implicated dysregulated long non-coding RNA (lncRNA) levels in the pathogenesis of type 2 diabetes (T2D). This study aimed to assess the expression of circulating HOTAIR and uc.48+, examining their correlation with clinical and biochemical variables in T2D patients, pre-diabetic individuals, and healthy controls. Methods: Peripheral blood levels ...


  • Effect of metformin on the long non-coding RNA expression levels in type 2 diabetes: an in vitro and clinical trial study

    by Seyedeh Nasrin Parvar, Ali Mirzaei, Ali Zare, Amir Hossein Doustimotlagh, Shekoofeh Nikooei, Arash Arya, Behnam Alipoor

    Background It has been suggested that the anti-hyperglycemic effect of metformin could be associated with its impact on long non-coding RNA (lncRNA) expression levels. Accordingly, in the current study, we evaluated the effect of metformin on the expression of H19, MEG3, MALAT1, and GAS5 in in vitro and in vivo situations. Methods The effect of hyperglycemia and metformin treatment on the lncRNAs expression level was evaluated in HepG2 cells. A total of 179 age- and sex-matched subjects, including 88 newly diagnosed patients with type 2 diabetes (T2D) and 91 healthy volunteers, were included in the case–control phase of the study. Moreover, 40 newly diagnosed patients participated in the study’s open-labeled non-controlled clinical trial phase. The expression levels of lncRNA in HepG2 cells and whole blood samples were determined using QRT-PCR. Results In vitro results showed that hyperglycemia induced H19 and MALAT1 and decreased GAS5 expression levels. Moreover, metformin decreased H19 and increased GAS5 expression in high glucose-treated cells. Case–control study findings revealed that the circulating levels of H19, MALAT1, and MEG3 were significantly elevated in T2D patients compared to the control subjects. Finally, results showed that the level of circulating H19 levels decreased while GAS5 increased in T2D patients after taking metformin for 2 months. Conclusion The results of the current study provided evidence that metformin could exert its effect in the treatment of T2D by altering the expression levels of H19 and GAS5.


  • Circulating expression levels of CircHIPK3 and CDR1as circular-RNAs in type 2 diabetes patients

    by Farzaneh Rezaeinejad, Ali Mirzaei, Bahman Khalvati, Gholamabbas Sabz, Behnam Alipoor

    Background Recent investigations suggested that deregulated levels of Circular RNAs (circRNAs) could be associated with type 2 diabetes mellitus (T2DM) pathogenesis. Accordingly, this study aimed to determine the expression levels of circulating CircHIPK3, CDR1as and their correlation with biochemical parameters in patients with T2DM, pre-diabetes and control subjects. Methods and results The expression of circRNAs in peripheral blood was determined using QRT-PCR in 70 patients with T2DM, 60 pre-diabetes and in 69 age and sex matched healthy controls. Moreover, bioinformatics tools were applied to explore and predict the potential interactions between circRNAs and other non-coding RNAs (ncRNAs). Our analysis revealed that the expression level of CircHIPK3 was significantly elevated in T2DM patients compared to healthy participants (P < 0.001) and pre-diabetes subjects (P = 0.018). In addition, ROC analysis suggested that at the cutoff value of 0.24 and the sensitivity and specificity of 50% and 88.4%, respectively, CircHIPK3 could distinguish between T2DM patients and control subjects. Furthermore, it was observed that the expression level of CDR1as is higher in pre-diabetic individuals than healthy individuals (P = 0.004). Finally, Spearman correlation analysis showed that there was a significant correlation between CircHIPK3 and CDR1as expression levels and clinical and anthropometrical parameters such as BMI, systolic and diastolic blood pressure, HbA1c and fasting blood glucose (P < 0.005). Conclusions The data of this study provided evidence that the expression levels of CircHIPK3, CDR1as increased in T2DM and pre-diabetes subjects, respectively.


  • Circular RNAs in β-cell function and type 2 diabetes-related complications: a potential diagnostic and therapeutic approach

    by Hassan Ghasemi, Zolfaghar Sabati, Hamid Ghaedi, Zaker Salehi, Behnam Alipoor

    Recent investigations have indicated that altered expression of non-coding RNAs (ncRNAs) could be associated with human diseases such as type 2 diabetes (T2D). Circular RNAs (circRNAs) are a new discovered class of ncRNAs with unique structural characteristics that involved in several molecular and cellular functions. Exploring of the circulating circRNAs as a reliable non-invasive biomarker for monitoring and diagnosing of human diseases has grown significantly. However, the molecular functions and clinical relevance of circRNAs are not yet well clarified in T2D. Accordingly, in this review, the involvement of circRNAs in the β-cell function and T2D-related complications is highlighted. The study also shed light on the possibility of using circRNAs as a biomarker for T2D diagnosis.


  • Co-expression profiling of plasma miRNAs and long noncoding RNAs in gastric cancer patients

    by Hamid Ghaedi, Mohammad Amin Nazer Mozaffari, Zaker Salehi, Hassan Ghasemi, Seyed Sajjad Zadian, Sadegh Alipoor, Shiva Hadianpour, Behnam Alipoor


  • Open Access

    Metformin attenuates oxidative stress and liver damage after bile duct ligation in rats

    by Amir Hossein Doustimotlagh, Heibatollah Sadeghi, Fatemeh Jahanbazi, Hossein Sadeghi, Navid Omidifar, Behnam Alipoor, Esmaeel Panahi Kokhdan, Seyed Mehdi Mousavipoor, Seyed Hossein Mousavi-Fard

    The aim of the current study was to investigate the antioxidative effect of metformin (MTF) on bile duct ligation (BDL)-induced hepatic disorder and histological damage in rats. The rats were divided into 4 groups including sham control (SC), BDL alone (BDL surgery), MTF1 (BDL surgery and administration of 250 mg/kg of MFM) and MTF2 (BDL surgery and administration of 500 mg/kg of MTF). After BDL, the animals treated with MTF by gavage for 10 days. Hematoxylin and eosin staining, biochemical analysis and oxidative stress markers were assayed to determine histological alterations, liver functions, and oxidant/antioxidant status. Hepatotoxicity was verified by remarkable increase in plasma levels of aminotransferases and alkaline phosphatase activity and liver histology 10 days after the BDL surgery. Our finding showed that treatment with MTF markedly reduced plasma alkaline phosphatase and alleviated liver injury indices (P ≤ 0.05). Furthermore, BDL caused a considerable increase in the protein carbonyl and malondialdehyde content (P ≤ 0.05). However, MTF reduces oxidative stress by constraining the protein oxidation and lipid peroxidation, and increases antioxidant reserve by increasing the ferric reducing ability of plasma and reducing glutathione levels. MTF exerts antioxidative effects in the liver fibrosis and may represent a hepato-protective effect when given to rats with BDL-induced hepatic injury.


  • Nanofiber-acellular dermal matrix as a bilayer scaffold containing mesenchymal stem cell for healing of full-thickness skin wounds

    by Mohamad Javad Mirzaei-Parsa, Hossein Ghanbari, Behnam Alipoor, Amirhossein Tavakoli, Mohammad Reza H. Najafabadi, Reza Faridi-Majidi

    Full-thickness skin defect is one of the main clinical problems, which cannot be repaired spontaneously. The aim of this study was to evaluate the feasibility of combining nanofibers with ADM as a bilayer scaffold for treatment of full-thickness skin wounds in a single-step procedure. The nanofibrous polycaprolactone/fibrinogen scaffolds were fabricated by electrospinning. Subsequently, mesenchymal stem cells were isolated from rat adipose tissues and characterized by flow cytometry. Cell adhesion, proliferation, and the epidermal differentiation potential of adipose-derived stem cells (ADSCs) on nanofibrous scaffolds were investigated by scanning electron microscopy (SEM), alamarBlue, and real-time PCR, respectively. In animal studies, full-thickness excisional wounds were created on the back of rats and treated with following groups: ADM, ADM-ADSCs, nanofiber, nanofiber-ADSCs, bilayer, and bilayer-ADSCs. In all groups, wounds were harvested on days 14 and 21 after treatment to evaluate re-epithelialization, blood vessel density, and collagen content. The results indicated that ADSCs seeded on ADM, nanofiber, and bilayer scaffolds can promote re-epithelialization, angiogenesis, and collagen remodeling in comparison with cell-free scaffolds. In conclusion, nanofiber-ADSCs showed the best results for re-epithelialization (according to histological scoring), average blood vessel density (92.7 ± 6.8), and collagen density (87.4 ± 4.9%) when compared to the control and other experimental groups.